Literature DB >> 21677249

Temporary interruption of deep brain stimulation for Parkinson's disease during outpatient electroconvulsive therapy for major depression: a novel treatment strategy.

Simon Ducharme1, Alice W Flaherty, Stephen J Seiner, Darin D Dougherty, Oscar G Morales.   

Abstract

The safety of electroconvulsive therapy (ECT) in patients with deep brain stimulation (DBS) has not been established. Cases reported had no adverse events, but DBS was withheld throughout the weeks of the ECT course. The authors report the first case of temporary interruption of DBS only during the minutes of each outpatient ECT.

Entities:  

Mesh：

Year:  2011        PMID： 21677249     DOI： 10.1176/jnp.23.2.jnp194

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN： 0895-0172            Impact factor:   2.198


  4 in total

1.  Catatonia after deep brain stimulation successfully treated with lorazepam and right unilateral electroconvulsive therapy: a case report.

Authors:  Davin K Quinn; Caleb Rees; Aaron Brodsky; Amanda Deligtisch; Daniel Evans; Mohamad Khafaja; Christopher C Abbott
Journal:  J ECT       Date:  2014-09       Impact factor: 3.635

2.  Interventional psychiatry: how should psychiatric educators incorporate neuromodulation into training?

Authors:  Nolan R Williams; Joseph J Taylor; Jonathan M Snipes; E Baron Short; Edward M Kantor; Mark S George
Journal:  Acad Psychiatry       Date:  2014-02-20

3.  High-Frequency Stimulation at the Subthalamic Nucleus Suppresses Excessive Self-Grooming in Autism-Like Mouse Models.

Authors:  Andrew D Chang; Victoria A Berges; Sunho J Chung; Gene Y Fridman; Jay M Baraban; Irving M Reti
Journal:  Neuropsychopharmacology       Date:  2015-11-26       Impact factor: 7.853

4.  Administration of electroconvulsive therapy for depression associated with deep brain stimulation in a patient with post-traumatic Parkinson's Disease: a case study.

Authors:  Miles G Cunningham; Golnaz Yadollahikhales; Gordana Vitaliano; Craig van Horne
Journal:  BMC Psychiatry       Date:  2016-11-15       Impact factor: 3.630
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.